Insider plans 3,540-share sale in NYSE: AEO common stock

Rhea-AI Filing Summary

AEO insider Jay Schottenstein has filed a notice of proposed stock sales under Rule 144. The filing covers the planned sale of 3,540 shares of common stock through broker Raymond James & Associates on the NYSE, with an aggregate market value of $92,840.00. The filing notes that there were 169,512,006 shares of this class outstanding.

The 3,540 shares were originally acquired on 04/13/1994 in the issuer’s IPO via an in kind exchange. The notice also lists recent activity: Jay Schottenstein sold 83,333 common shares on 01/20/2026 for gross proceeds of $2,103,485.88, and 87,891 common shares on 01/21/2026 for gross proceeds of $2,268,003.73. The signer represents that they are not aware of any undisclosed material adverse information about the issuer’s operations.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Raymond James & Associates 880 Carillon Parkway St. Petersburg FL 33716	3540	92840.00	169512006	01/22/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	04/13/1994	IPO	Issuer			3540	04/13/1994	In Kind Exchange

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Jay Schottenstein 4300 E 5th Ave Columbus OH 43219	Common	01/20/2026	83333	2103485.88
Jay Schottenstein 4300 E 5th Ave Columbus OH 43219	Common	01/21/2026	87891	2268003.73

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filing for AEO disclose?

The Form 144 filing discloses that Jay Schottenstein intends to sell 3,540 shares of common stock on the NYSE through Raymond James & Associates, with an aggregate market value of $92,840.00. It also reports recent sales of additional shares over the prior three months.

How many AEO shares does the insider plan to sell and through which broker?

The insider plans to sell 3,540 shares of common stock through Raymond James & Associates, located at 880 Carillon Parkway, St. Petersburg, FL 33716, with the NYSE named as the securities exchange.

When were the planned Form 144 AEO share sales expected to occur?

The approximate date of sale listed in the filing is 01/22/2026 for the 3,540 common shares to be sold on the NYSE.

What prior AEO stock sales by Jay Schottenstein are reported in the last three months?

The filing reports that Jay Schottenstein sold 83,333 common shares on 01/20/2026 for gross proceeds of $2,103,485.88, and 87,891 common shares on 01/21/2026 for gross proceeds of $2,268,003.73.

How many AEO common shares are outstanding according to this Form 144?

The filing states that the number of common shares outstanding is 169,512,006 for the class of securities referenced in the planned sale.

How and when did the insider originally acquire the AEO shares being sold?

The 3,540 common shares to be sold were acquired on 04/13/1994 in the issuer’s IPO, identified as an In Kind Exchange, with payment also dated 04/13/1994.

What representation does the insider make about non-public information in this AEO filing?

By signing the notice, the person for whose account the securities are to be sold represents that they do not know any material adverse information about the issuer’s current or prospective operations that has not been publicly disclosed.